{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Carcinoma&page=12",
    "query": {
      "condition": "Breast Carcinoma",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 6987,
    "total_pages": 699,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Carcinoma&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Carcinoma&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T04:04:49.291Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00019500",
      "title": "Raloxifene in Preventing Breast Cancer in Premenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "raloxifene",
          "type": "DRUG"
        },
        {
          "name": "evaluation of cancer risk factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "47 Years",
        "sex": "FEMALE",
        "summary": "23 Years to 47 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "1998-12",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019500"
    },
    {
      "nct_id": "NCT01349322",
      "title": "Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Standard fractionation whole breast irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Hypofractionated whole breast irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Concurrent boost",
          "type": "RADIATION"
        },
        {
          "name": "Sequential boost",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2354,
      "start_date": "2011-05-24",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 386,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349322"
    },
    {
      "nct_id": "NCT03589339",
      "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiotherapy",
        "Immunotherapy",
        "Microsatellite Instability-High Solid Malignant Tumour",
        "Metastasis From Malignant Tumor of Liver",
        "Squamous Cell Carcinoma of Head and Neck",
        "Metastasis From Malignant Tumor of Cervix",
        "Metastatic Renal Cell Carcinoma",
        "Metastasis From Malignant Melanoma of Skin (Disorder)",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic NSCLC",
        "Metastasis From Malignant Tumor of Bladder (Disorder)"
      ],
      "interventions": [
        {
          "name": "NBTXR3",
          "type": "DRUG"
        },
        {
          "name": "SABR",
          "type": "RADIATION"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Nanobiotix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2019-01-16",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03589339"
    },
    {
      "nct_id": "NCT03572153",
      "title": "A Mind-Body Intervention for Hot Flash Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hot Flashes",
        "Postmenopausal Symptoms",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Self-Administered Hypnosis",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Self-Administered White Noise Hypnosis",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Baylor University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 250,
      "start_date": "2019-03-04",
      "completion_date": "2024-02-16",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Waco, Texas",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Waco",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03572153"
    },
    {
      "nct_id": "NCT00920257",
      "title": "A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK2141795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2009-06-16",
      "completion_date": "2013-04-17",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920257"
    },
    {
      "nct_id": "NCT03125902",
      "title": "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 653,
      "start_date": "2017-08-25",
      "completion_date": "2023-01-17",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 8,
      "location_summary": "Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03125902"
    },
    {
      "nct_id": "NCT02954900",
      "title": "Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "RealRisks",
          "type": "OTHER"
        },
        {
          "name": "BNAV",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 75 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2016-03-15",
      "completion_date": "2018-10",
      "has_results": false,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02954900"
    },
    {
      "nct_id": "NCT00140140",
      "title": "A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage IV (Metastatic) Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ABI-007",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2005-08",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2019-11-26",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Seattle, Washington",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00140140"
    },
    {
      "nct_id": "NCT01525589",
      "title": "A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PM01183",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaMar",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 111,
      "start_date": "2012-06-13",
      "completion_date": "2018-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525589"
    },
    {
      "nct_id": "NCT05959291",
      "title": "Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HER2-positive Metastatic Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Discontinuation of Anti-HER-2 Maintenance Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-07-17",
      "completion_date": "2030-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-15T04:04:49.291Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05959291"
    }
  ]
}